Pathophysiology and pharmacology

The most prominent pathological lesion observed in PD occurs in the basal ganglia of the brain’s extra-pyramidal system. Non-PD patients and without nigrostriatal degeneration develope dyskinesias in response to dopaminergic. It is caused by gradual loss of nerve cells in the brain area called nigra and also by low and falling dopamine levels. The worldwide prevalence of Parkinson disease is anticipated to grow to 2.89 million cases worldwide by 2022.

  • Structure-Function Relationships of Erythropoitein
  • Primary Hemopoietic Disorders

Related Conference of Pathophysiology and pharmacology

Aug 02-04, 2017

International Meeting on CNS

Melbourne, Australia
August 29-31, 2017

15th European Neurology Congress

London, UK
August 29-31, 2017

6th World Congress on Addiction Disorder & Addiction Therapy

Prague, Czech Republic
August 31-September 01, 2017

3rd International Conference on Epilepsy and Treatment

Brussels, Belgium
September 07-08, 2017

Global Experts Meeting on Brain Disorders

Macau, Hong Kong
Oct 12-13, 2017

Internatinal Meeting on Addiction Congress

Osaka, Japan
Oct 12-13, 2017

Global Meeting on Dual Diagnosis and Addiction

Auckland, Newzeland
October 16-17, 2017

17th Global Neuroscience Conference

Osaka, Japan
Nov 13-14, 2017

Gobal Experts Meeting on Neuroscience and Neurochemistry

Melbourne, Australia
February 22-23, 2018

11th International Conference on Vascular Dementia

Paris, France

Pathophysiology and pharmacology Conference Speakers

Recommended Sessions

Related Journals

Are you interested in